Immunome, Inc. (NASDAQ:IMNM) CEO Clay B. Siegall Acquires 137,100 Shares

Immunome, Inc. (NASDAQ:IMNM) CEO Clay B. Siegall bought 137,100 shares of the firm’s stock in a transaction on Wednesday, March 26th. The shares were bought at an average price of $7.29 per share, with a total value of $999,459.00. Following the completion of the purchase, the chief executive officer now owns 806,736 shares in the company, valued at approximately $5,881,105.44. The trade was a 20.47 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Immunome Stock Up 2.7 %

Shares of IMNM opened at $7.28 on Friday. The business has a 50-day simple moving average of $9.56 and a two-hundred day simple moving average of $11.38. Immunome, Inc. has a 52 week low of $6.94 and a 52 week high of $25.75. The stock has a market cap of $633.00 million, a price-to-earnings ratio of -0.90 and a beta of 1.93.

Immunome (NASDAQ:IMNM) last released its earnings results on Wednesday, March 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.16). Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. The firm had revenue of $2.74 million during the quarter, compared to analysts’ expectations of $3.07 million. On average, equities analysts anticipate that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.

Institutional Trading of Immunome

A number of hedge funds and other institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets purchased a new position in shares of Immunome during the 4th quarter valued at $70,000. KLP Kapitalforvaltning AS bought a new stake in Immunome during the fourth quarter valued at about $75,000. AlphaQuest LLC lifted its position in shares of Immunome by 786,700.0% in the fourth quarter. AlphaQuest LLC now owns 7,868 shares of the company’s stock valued at $84,000 after acquiring an additional 7,867 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Immunome by 482.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company’s stock worth $91,000 after acquiring an additional 7,129 shares during the period. Finally, Aquatic Capital Management LLC purchased a new stake in shares of Immunome during the fourth quarter worth about $95,000. 44.58% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts recently commented on IMNM shares. Stephens reaffirmed an “overweight” rating and issued a $30.00 price objective on shares of Immunome in a report on Thursday, March 20th. Guggenheim cut their price target on Immunome from $35.00 to $25.00 and set a “buy” rating for the company in a research note on Thursday, March 20th. Lifesci Capital started coverage on shares of Immunome in a research note on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 price objective on the stock. Finally, Wedbush reissued an “outperform” rating and issued a $33.00 price objective on shares of Immunome in a report on Thursday, March 20th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $25.50.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.